daytrading august 1 pre-market, page-2

Thanks HLL

Bit quite here today


PAB

PAT-SM6 to treat multiple myeloma
2 out of 8 patients have shown evidence of stable disease, analysed at day +35 post treatment.

Point to consider: Patients in this trial are resistant to all currently marketed drugs and have a large disease burden.

Next announcement traders are anticipating is the approval to commence administering PAT-SM6 to patients in cohort 4 where patients receive twice the dosage strength to those in the previous group.

3 patients per group, trial ends Q4 2013

Biotech $20M mc .....$5M cash at bank.


What did Big Pharma pay for a slice of the action in this space as recent as this week for a drug in a Phase 1b clinical trial.......

http://www.fiercebiotech.com/story/celgene-spends-100m-option-buy-myeloma-drug-developer-acetylon/2013-07-29